Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ
Hoth Therapeutics, Inc. (NASDAQ:HOTH) has reported promising proof-of-concept data for its Alzheimer's disease therapeutic, HT-ALZ, following a study on aged APP/PS1+/- mice. Using doses of 20mg/kg and 40mg/kg, results indicated significant cognitive improvements, including reduced anxiety levels and enhanced spatial memory performance in maze tests. The research, conducted with Washington University in St. Louis, highlights HT-ALZ's potential under the 505(b)(2) regulatory pathway. Previous studies also demonstrated a notable decrease in brain amyloid β levels after acute treatment with HT-ALZ.
- Significant cognitive improvements observed in Alzheimer's disease mouse model with HT-ALZ.
- Reduction in anxiety-like behavior noted in treated mice.
- Higher doses (20mg/kg and 40mg/kg) showed the most benefit in spatial memory performance.
- Proof-of-concept data supports therapeutic potential of HT-ALZ.
- None.
HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model and
Results Show Reduced Anxiety and Improved Performance
Hoth reports that the longer treatment before beginning of testing is improving performance of more mice in the water maze and appears to have a positive effect on anxiety-like behavior in the elevated plus maze. The groups of mice treated with the higher doses, 20mg/kg and 40mg/kg of HT-ALZ, appear to have the most benefit, with the 20mg group already showing significant improvement in spatial memory in the water maze. The elevated plus maze test is one of the most widely used tests for measuring anxiety-like behavior. The test is based on the natural aversion of mice for open and elevated areas, as well as on their natural spontaneous exploratory behavior in novel environments.
AD is a neurodegenerative disease that is characterized by aggregates of amyloid β (Aβ) plaques and neurofibrillary tangles of Tau protein in the brain, which contribute to the clinical symptoms of the disease such as dementia. Previously Hoth reported study results focused on investigating the effect of orally administered HT-ALZ to reduce the concentration of Aβ in the brain interstitial fluid, using an established Alzheimer's Disease mouse model (aged APP/PS1+/- mice). The initial data from those studies showed a significant decrease in Aβ in both male and female APP/PS1+/- mice after acute treatment with HT-ALZ, compared to placebo-treated animals and baseline Aβ levels.
About
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the
Investor Contact:
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-increased-positive-results-of-its-alzheimers-therapeutic-ht-alz-301741890.html
SOURCE
FAQ
What are the latest results for Hoth Therapeutics' HT-ALZ?
What doses of HT-ALZ were tested in the latest study?
How did HT-ALZ affect anxiety-like behavior in mice?
Who conducted the research on HT-ALZ?
What is the regulatory pathway for HT-ALZ?
